Inhibiting Cav-1, clathrin, or EEA1 using siRNAs against these components led to the recovery of PM-localized KCa2.3 and KCa3.1 levels, suggesting that siRNAs against these components can be used to treat endothelial dysfunction. The gene discussed is EEA1; the disease is endothelial dysfunction.